Tsagareli Merab G, Nozadze Ivliane, Tsiklauri Nana, Carstens Mirela Iodi, Gurtskaia Gulnaz, Carstens E
Beritashvili Center for Experimental Biomedicine, Tbilisi, Georgia.
Beritashvili Center for Experimental Biomedicine, Tbilisi, Georgia.
Neuroscience. 2020 Nov 21;449:35-45. doi: 10.1016/j.neuroscience.2020.09.048. Epub 2020 Oct 1.
Acute itch is elicited by histamine, as well as non-histaminergic itch mediators including chloroquine, BAM8-22 and Ser-Leu-Ile-Gly-Arg-Leu (SLIGRL). When injected intradermally, histamine binds to histamine H1 and H4 receptors that activate transient receptor potential vanilloid 1 (TRPV1) to depolarize pruriceptors. Chloroquine, BAM8-22, and SLIGRL, respectively, bind to Mas-related G-protein-coupled receptors MrgprA3, MrgprC11, and MrgprC11/PAR2 that in turn activate transient receptor potential ankyrin 1 (TRPA1). In this study we tested if histamine, chloroquine, BAM8-22 and SLIGRL elicit thermal hyperalgesia and mechanical allodynia in adult male mice. We measured the latency of hindpaw withdrawal from a noxious heat stimulus, and the threshold for hindpaw withdrawal from a von Frey mechanical stimulus. Intraplantar injection of histamine resulted in significant thermal hyperalgesia (p < 0.001) and mechanical allodynia (p < 0.001) ipsilaterally that persisted for 1 h. Pretreatment with the TRPV1 antagonist AMG-517 (10 or 20 μg), but not the TRPA1 antagonist HC-030031 (50 or 100 μg), significantly attenuated the magnitude and time course of thermal hyperalgesia and mechanical allodynia elicited by histamine (p < 0.001 for both), indicating that these effects are mediated by TRPV1. In contrast, pretreatment with the TRPA1 antagonist significantly reduced thermal hyperalgesia and mechanical allodynia elicited by chloroquine (p < 0.001 for both ), BAM-822 (p < 0.01, p < 0.001, respectively) and SLGRL (p < 0.05, p < 0.001, respectively), indicating that effects elicited by these non-histaminergic itch mediators require TRPA1. TRPV1 and TRPA1 channel inhibitors thus may have potential use in reducing hyperalgesia and allodynia associated with histaminergic and non-histaminergic itch, respectively.
急性瘙痒由组胺以及包括氯喹、BAM8-22和丝氨酸-亮氨酸-异亮氨酸-甘氨酸-精氨酸-亮氨酸(SLIGRL)在内的非组胺能瘙痒介质引发。皮内注射时,组胺与组胺H1和H4受体结合,激活瞬时受体电位香草酸亚型1(TRPV1),使瘙痒感受器去极化。氯喹、BAM8-22和SLIGRL分别与Mas相关G蛋白偶联受体MrgprA3、MrgprC11以及MrgprC11/PAR2结合,进而激活瞬时受体电位锚蛋白1(TRPA1)。在本研究中,我们测试了组胺、氯喹、BAM8-22和SLIGRL是否会在成年雄性小鼠中引发热痛觉过敏和机械性异常性疼痛。我们测量了后爪从有害热刺激中撤回的潜伏期,以及后爪从von Frey机械刺激中撤回的阈值。足底注射组胺会导致同侧显著的热痛觉过敏(p < 0.001)和机械性异常性疼痛(p < 0.001),并持续1小时。用TRPV1拮抗剂AMG-517(10或20μg)预处理,但不用TRPA1拮抗剂HC-030031(50或100μg)预处理,可显著减轻组胺引发的热痛觉过敏和机械性异常性疼痛的程度及时程(两者均p < 0.001),表明这些效应是由TRPV1介导的。相反,用TRPA1拮抗剂预处理可显著降低氯喹(两者均p < 0.001)、BAM-822(分别为p < 0.01、p < 0.001)和SLGRL(分别为p < 0.05、p < 0.001)引发的热痛觉过敏和机械性异常性疼痛,表明这些非组胺能瘙痒介质引发的效应需要TRPA1。因此,TRPV1和TRPA1通道抑制剂可能分别具有减轻与组胺能和非组胺能瘙痒相关的痛觉过敏和异常性疼痛的潜在用途。